Advertisement
Organisation › Details
Acticor Biotech (Group)
Acticor Biotech is a clinical stage biotechnology company, a spin-off of INSERM (the French National Institute of Health and Medical Research), dedicated to developing an innovative treatment for cardiovascular emergencies, including ischemic stroke. Acticor Biotech has been built on the expertise and research undertaken by its co-founders: Dr. Martine Jandrot-Perrus at INSERM Paris,Prof. Philippe Billiald at Paris-Sud University and Dr Gilles Avenard. Acticor Biotech is a partner in the BOOSTER consortium, dedicated to the management of, and novel treatments for, cerebrovascular accidents in emergency situations. Acticor Biotech is supported by a panel of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and Armesa Foundation. *
Start | 2013-11-26 established (s-off) | |
Today | Acticor Biotech SAS | |
Predecessor | Inserm (National Institute for Health and Medical Research, FR) | |
Industry | antibody fragment (Fab) | |
Industry 2 | glenzocimab (ACT017) | |
Person | Avenard, Gilles (Acticor Biotech 201612 CEO) | |
Region | Paris | |
Country | France | |
Street | 46 rue Henri Huchard Hôpital Bichat – Bâtiment Inserm U1148 | |
City | 75018 Paris | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Euronext N.V.. (11/2/21). "Press Release: Acticor Biotech Lists on Euronext Growth Paris". Paris. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Acticor Biotech (Group)
- [1] Euronext N.V.. (11/2/21). "Press Release: Acticor Biotech Lists on Euronext Growth Paris". Paris....
- [2] Acticor Biotech SAS. (11/6/19). "Press Release: Acticor Biotech Raises €7m in Addition to Its Series B Financing, Now Completed at €22.3m". Paris....
- [3] Acticor Biotech SAS. (11/5/19). "Press Release: Acticor Biotech Partner of the BOOSTER Consortium Dedicated to Management and New Treatments of Stroke in Emergeny Situations". Paris....
- [4] Acticor Biotech SAS. (10/17/18). "Press Release: Acticor Biotech Raises €15.3M in a Series B Financing". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top